var data={"title":"Oxybutynin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Oxybutynin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6698?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=oxybutynin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Oxybutynin: Patient drug information&quot;</a> and <a href=\"topic.htm?path=oxybutynin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Oxybutynin: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204694\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Ditropan XL;</li>\n      <li>Gelnique;</li>\n      <li>Gelnique Pump;</li>\n      <li>Oxytrol;</li>\n      <li>Oxytrol For Women [OTC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204695\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Ditropan XL;</li>\n      <li>Gelnique;</li>\n      <li>Oxybutyn;</li>\n      <li>Oxybutynine;</li>\n      <li>Oxytrol</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204735\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antispasmodic Agent, Urinary</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204698\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Overactive bladder:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Oral:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release: 5 mg 2 to 3 times daily; maximum: 5 mg 4 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release: Initial: 5 to 10 mg once daily, adjust dose in 5 mg increments at weekly intervals; maximum: 30 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Topical gel: </i>Apply contents of 1 sachet (100 mg/g) or 1 actuation of the pump (100 mg/g) once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Transdermal:</i> Apply one 3.9 mg/day patch twice weekly (every 3 to 4 days)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204716\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=oxybutynin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Oxybutynin: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">\n      <b>Neurogenic/Overactive bladder:</b> Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Immediate release: Children: &gt;5 years and Adolescents: 5 mg twice daily; maximum: 5 mg 3 times daily </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Extended release: Children &ge;6 years and Adolescents: 5 mg once daily; adjust dose as needed in 5 mg increments at weekly intervals; maximum: 20 mg once daily</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204699\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <i>Oral:</i> Immediate release: Initial: 2.5 mg 2 to 3 times daily; increase cautiously</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <i>Topical gel, transdermal patch:</i> Refer to adult dosing. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14266259\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied); use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14266260\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied); use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204669\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gel, Transdermal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gelnique: 3% (92 g [DSC]) [contains propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gel, Transdermal, as chloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gelnique: 10% (1 g) [contains alcohol, usp]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gelnique Pump: 10% (30 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Patch Twice Weekly, Transdermal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oxytrol: 3.9 mg/24 hr (1 ea, 2 ea [DSC], 4 ea [DSC], 8 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oxytrol For Women: 3.9 mg/24 hr (4 ea, 8 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Syrup, Oral, as chloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg/5 mL (473 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as chloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release 24 Hour, Oral, as chloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ditropan XL: 5 mg, 10 mg, 15 mg [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg, 10 mg, 15 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204653\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204672\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Administer without regard to meals. Extended release tablets must be swallowed whole with liquid; do not crush, divide, or chew; take at approximately the same time each day.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topical gel: For topical use only. Apply to clean, dry, intact skin on abdomen, thighs, or upper arms/shoulders. Rotate application sites; do not apply to the same site on consecutive days. Wash hands after use. Cover treated area with clothing after gel has dried to prevent transfer of medication to others. Do not bathe, shower, or swim until 1 hour after gel applied. Do not apply to recently shaved skin.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pump: Prior to initial use, prime pump several times (&ge; 4 times) until gel begins to come out; after gel is observed, fully depress the pump one more time and discard gel dispensed from pump during priming.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Transdermal: Apply to clean, dry skin on abdomen, hip, or buttock; do not apply to areas treated with oils, lotions, or powders. Select a new site for each new system (avoid reapplication to same site within 7 days); change the patch on the same 2 days each week. Avoid rubbing the patch area during bathing, swimming, showering, or exercising. Wear patch under clothing; do not expose to sunlight.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204671\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Overactive bladder:</b> Treatment of symptoms associated with overactive uninhibited neurogenic or reflex neurogenic bladder (eg, urgency, frequency, leakage, urge incontinence, dysuria); treatment of symptoms associated with detrusor overactivity due to a neurological condition (eg, spina bifida) (extended release tablet only).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204742\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Oxybutynin may be confused with OxyCONTIN</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Ditropan may be confused with Detrol, diazePAM, Diprivan, dithranol</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Oxybutynin is identified in the Beers Criteria as a potentially inappropriate medication in patients 65 years and older due to its strong anticholinergic properties (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Transdermal patch may contain conducting metal (eg, aluminum); remove patch prior to MRI.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204660\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Oral:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (5% to 17%), drowsiness (6% to 14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Xerostomia (35% to 72%), constipation (9% to 15%), nausea (5% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Decreased blood pressure (1% to &lt;5%), edema (1% to &lt;5%), flushing (1% to &lt;5%), increased blood pressure (1% to &lt;5%), palpitations (1% to &lt;5%), peripheral edema (1% to &lt;5%), sinus arrhythmia (1% to &lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (8%), nervousness (7%), insomnia (3% to 6%), confusion (1% to &lt;5%), falling (1% to &lt;5%), fatigue (3%), flank pain (1% to &lt;5%), pain (1% to &lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Xeroderma (2% to 3%), pruritus (1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Fluid retention (&lt;5%), increased thirst (&lt;5%), increased serum glucose (1% to &lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (7% to 8%), dyspepsia (5% to 6%), coated tongue (1% to &lt;5%), eructation (1% to &lt;5%), upper abdominal pain (1% to &lt;5%), flatulence (1% to 3%), abdominal pain (2%), dysgeusia (2%), vomiting (1% to 2%), gastroesophageal reflux disease (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary hesitancy (2% to 9%), urinary tract infection (7%), urinary retention (1% to 6%), cystitis (1% to &lt;5%), pollakiuria (1% to &lt;5%), increased post-void residual urine volume (2% to 4%), dysuria (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Fungal infection (1% to &lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (1% to &lt;5%), back pain (1% to &lt;5%), limb pain (1% to &lt;5%), weakness (1% to &lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Blurred vision (4% to 10%), eye irritation (1% to &lt;5%), keratoconjunctivitis sicca (1% to &lt;5%), xerophthalmia (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Dry nose (2% to 5%), asthma (1% to &lt;5%), bronchitis (1% to &lt;5%), hoarseness (1% to &lt;5%), nasal congestion (1% to &lt;5%), nasopharyngitis (1% to &lt;5%), pharyngolaryngeal pain (1% to &lt;5%), sinus congestion (1% to &lt;5%), sinus headache (1% to &lt;5%), upper respiratory tract infection (1% to &lt;5%), cough (2% to 3%), dry throat (2% to 3%), oropharyngeal pain (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Topical gel:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (3%), fatigue (2%), headache (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Xerostomia (8%), viral gastroenteritis (2%), constipation (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Application site reaction (5%), application site dermatitis (2%), application site pruritus (2%),</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Upper respiratory tract infection (5%), nasopharyngitis (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Transdermal:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Local: Application site pruritus (14% to 17%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Macular eruption (application site: 3%)</p>\n    <p style=\"text-indent:-4em;margin-left:6em;\">Gastrointestinal: Xerostomia (4% to 10%), constipation (3%), diarrhea (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Dysuria (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Application site erythema (6% to 8%), application site vesicles (3%), application site rash (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Visual disturbance (3%)</p>\n    <p style=\"text-indent:0em;\">&lt;1%, postmarketing, and/or case reports: Agitation, anaphylaxis, angioedema, anorexia, cardiac arrhythmia, chest discomfort, confusion, cycloplegia, decreased gastrointestinal motility, decreased lactation, delirium, dizziness, drowsiness, dysphagia, facial edema, frequent bowel movements, glaucoma, hallucination, headache, hot flash, hypersensitivity reaction, hypertension, hypohidrosis, impotence, memory impairment, mydriasis, prolonged Q-T interval on ECG, psychotic reaction, seizure, skin rash, tachycardia, urticaria, voice disorder</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204675\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to oxybutynin or any component of the formulation; patients with or at risk for uncontrolled narrow-angle glaucoma, urinary retention, gastric retention or conditions with severely decreased GI motility.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OTC labeling: When used for self-medication, do not use if you have pain or burning when urinating, blood in urine, unexplained lower back or side pain, cloudy or foul-smelling urine; in males; age &lt;18 years; only experience accidental urine loss when cough, sneeze, or laugh; diagnosis of urinary or gastric retention; glaucoma; hypersensitivity to oxybutynin.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Severe GI conditions; myasthenia gravis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204657\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Angioedema/hypersensitivity reactions: May cause hypersensitivity, including anaphylaxis and angioedema. Cases of angioedema involving the face, lips, tongue, and/or larynx have been reported with oral oxybutynin; some cases have occurred after a single dose. Discontinue immediately if tongue, hypopharynx, or larynx is involved; promptly initiate appropriate management.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: Anticholinergics may cause agitation, confusion, drowsiness, dizziness, hallucinations, headache, somnolence, and/or blurred vision, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Dose reduction or discontinuation should be considered if CNS effects occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heat prostration: May increase the risk of heat prostration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bladder flow obstruction: Use with caution in patients with bladder flow obstruction; may increase the risk of urinary retention.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with CAD, heart failure, hypertension, and/or cardiac arrhythmias; may exacerbate condition.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dementia: Use with caution in patients with dementia treated with cholinesterase inhibitors; may aggravate symptoms of disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; GI disorders: Use with caution in patients with decreased GI motility or GI obstructive disorders; may increase the risk of gastric retention. Use with caution in patients with ulcerative colitis, intestinal atony, pyloric stenosis, gastroesophageal reflux, or with medications that may cause or exacerbate esophagitis (eg, bisphosphonates). In patients with ulcerative colitis, use may decrease gastric motility to the point of increasing the risk of paralytic ileus or toxic megacolon.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Glaucoma: Use with caution in patients with treated angle-closure glaucoma; may exacerbate condition; use is contraindicated with uncontrolled narrow-angle glaucoma.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment (limited experience).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hiatal hernia: Use with caution in patients with hiatal hernia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperthyroidism: Use with caution in patients with hyperthyroidism; may exacerbate condition.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myasthenia gravis: Avoid use in patients with myasthenia gravis; may exacerbate condition. Discontinue therapy if signs/symptoms occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neuropathy: Use with caution in patients with autonomic neuropathy; may aggravate symptoms of decreased GI motility.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Parkinson disease: Use with caution in patients with Parkinson disease; may aggravate symptoms of disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture; may cause urinary retention.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment (limited experience).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extended release formulation: The extended release formulation consists of drug within a nondeformable matrix; following drug release/absorption, the matrix/shell is expelled in the stool. The use of nondeformable products in patients with known stricture/narrowing of the GI tract has been associated with symptoms of obstruction (rare).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Topical gel: To minimize transferring medication to others, cover treatment area with clothing after gel has dried. Discontinue use if skin irritation occurs. Contains ethanol; do not expose to open flame or smoking until gel has dried.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Transdermal patch: May contain conducting metal (eg, aluminum); remove patch prior to MRI.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; OTC labeling: Other causes of frequent urination (UTI, diabetes, early pregnancy, other serious conditions) may need to be considered prior to use. Patients should contact a health care provider if symptoms do not improve within 2 weeks of initial use or for new or worsening symptoms.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204730\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204662\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9728&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May enhance the CNS depressant effect of Oxybutynin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amantadine: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifampridine: May diminish the anticholinergic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Amifampridine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabinoid-Containing Products: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoid-Containing Products. <b> Exceptions: </b>Cannabidiol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Oxybutynin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: Anticholinergic Agents may enhance the adverse/toxic effect of Opioid Analgesics. Specifically, the risk for constipation and urinary retention may be increased with this combination. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204665\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204677\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events  were not observed in animal reproduction studies. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204678\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if oxybutynin is present in breast milk. According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. Suppression of lactation has been reported.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204679\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Food causes a slight delay in the absorption of the oral solution and bioavailability is increased by ~25%. Absorption of the extended release tablet is not affected by food. May be taken without regard to meals. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204667\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Incontinence episodes, postvoid residual (PVR), anticholinergic reactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204656\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Direct antispasmodic effect on smooth muscle, also inhibits the action of acetylcholine on smooth muscle (exhibits <sup>1</sup>/<sub>5</sub> the anticholinergic activity of atropine, but has 4-10 times the antispasmodic activity); does not block effects at skeletal muscle or at autonomic ganglia; increases bladder capacity, decreases uninhibited contractions, and delays desire to void, therefore, decreases urgency and frequency</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204674\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Oral: Immediate release: 30 to 60 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peak effect: Immediate release: 3 to 6 hours; Extended release: 3 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Oral: Immediate release: 6 to 10 hours; Extended release: Up to 24 hours; Transdermal 96 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Oral: Rapid and well absorbed; Transdermal: High</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: IV: V<sub>d</sub>: 193 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: &gt;99% primarily to alpha<sub>1</sub>-acid glycoprotein</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic via CYP3A4; Oral: High first-pass metabolism; forms active and inactive metabolites</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Oral: Immediate release: 6% (range: 1.6% to 10.9%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: IV: ~2 hours (parent drug), 7 to 8 hours (metabolites); Oral: Immediate release: ~2 to 3 hours; Extended release: ~13 hours; Transdermal: 64 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: Oral: Immediate release: ~60 minutes; Extended release: 4 to 6 hours; Transdermal: 24 to 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (&lt;0.1% as metabolites and unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204676\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (Gelnique Pump Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10% (30 g): $452.46</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (Gelnique Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10% (1 g): $15.08</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch, twice-weekly</b> (Oxytrol For Women Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3.9 mg/24 hrs (4): $13.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch, twice-weekly</b> (Oxytrol Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3.9 mg/24 hrs (1): $97.21</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Syrup</b> (Oxybutynin Chloride Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/5 mL (473 mL): $51.95</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Ditropan XL Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $762.56</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $763.34</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (100): $782.46</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Oxybutynin Chloride ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $328.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $328.75</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (100): $336.95</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Oxybutynin Chloride Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $76.03</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204680\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Ao Ning (CN);</li>\n      <li>Butyn (PK);</li>\n      <li>Cystrin (GB, IE);</li>\n      <li>Delifon (CO);</li>\n      <li>Ditropan (AE, AR, AT, AU, BE, CH, CY, CZ, ES, FI, FR, GB, GR, HN, HU, IE, IT, JO, KR, KW, LB, LU, MT, PL, PT, SE, TW);</li>\n      <li>Ditropan XL (BB);</li>\n      <li>Diutropan (TH);</li>\n      <li>Dresplan (ES);</li>\n      <li>Dridase (DE, NL);</li>\n      <li>Driptane (EE, HR, LB, LV, PH, RU, VN);</li>\n      <li>Dryptan (UA);</li>\n      <li>Frenurin (BR);</li>\n      <li>Gradual (UY);</li>\n      <li>Inprax (MX);</li>\n      <li>Kentera (AT, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HN, HR, IE, IT, MT, NL, NO, PL, PT, RO, RU, SE, SK, TR);</li>\n      <li>Kentera Patch (GB, IE);</li>\n      <li>Lenditro (ZA);</li>\n      <li>Lyrinel (IL, MX, TH);</li>\n      <li>Lyrinel Oros SR (KR);</li>\n      <li>Lyrinel XL (GB, IE);</li>\n      <li>Mutum (EC);</li>\n      <li>Mutum CR (EC);</li>\n      <li>Nefryl (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Neoxy Tape (JP);</li>\n      <li>Newin (TW);</li>\n      <li>Novitropan (IL);</li>\n      <li>Obutin (SG);</li>\n      <li>Odranal (CL);</li>\n      <li>Oxyban (TW);</li>\n      <li>Oxyspas (LK);</li>\n      <li>Oxytrol (AU, NZ);</li>\n      <li>Pollakisu (JP);</li>\n      <li>Reteven (PE, VE);</li>\n      <li>Socliden (PY);</li>\n      <li>Sybutin (UA);</li>\n      <li>Tavor (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Tropan (IN);</li>\n      <li>Uricon CR (BD);</li>\n      <li>Urihexal (ZA);</li>\n      <li>Uroflax (PY);</li>\n      <li>Uropan (TR);</li>\n      <li>Uroxal (HU);</li>\n      <li>Voxytane (MY)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2015;63(11):2227-2246. doi:10.1111/jgs.13702<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxybutynin-drug-information/abstract-text/26446832/pubmed\" target=\"_blank\" id=\"26446832\">26446832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ditropan XL (oxybutynin) [prescribing information]. Titusville, NJ: Janssen; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gelnique (oxybutynin) gel prescribing information]. Irvine, CA: Allergan USA Inc; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gelnique (oxybutynin) [product monograph]. Markham, Ontario, Canada: Allergan Pharma; March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Katz IR, Sands LP, Bilker W, et al, &quot;Identification of Medications That Cause Cognitive Impairment in Older People: The Case of Oxybutynin Chloride,&quot; <i>J Am Geriatr Soc</i>,1998, 46(1):8-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxybutynin-drug-information/abstract-text/9434659/pubmed\" target=\"_blank\" id=\"9434659\">9434659</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Oxybutynin chloride solution (immediate release) [prescribing information]. Huntsville, AL: Qualitest Pharmaceuticals; March 2008</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Oxybutynin chloride tablet (immediate release) [prescribing information]. Minneapolis, MN: Upsher-Smith Laboratories; May 2012</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Oxytrol for Women (oxybutynin) [prescribing information]. Whippany, NJ: Bayer HealthCare LLC; received March 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Oxytrol (oxybutynin) [product monograph]. Markham, Ontario, Canada: Allergan Pharma; February 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Oxytrol (oxybutynin) transdermal system [prescribing information]. Irvine, CA: Allergan USA Inc; October 2017.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9728 Version 216.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F204694\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F204695\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F204735\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F204698\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F204716\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F204699\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F14266259\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F14266260\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F204669\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F204653\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F204672\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F204671\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F204742\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F204660\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F204675\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F204657\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F204730\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F204662\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F204665\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F204677\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F204678\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F204679\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F204667\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F204656\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F204674\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F204676\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F204680\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9728|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=oxybutynin-patient-drug-information\" class=\"drug drug_patient\">Oxybutynin: Patient drug information</a></li><li><a href=\"topic.htm?path=oxybutynin-pediatric-drug-information\" class=\"drug drug_pediatric\">Oxybutynin: Pediatric drug information</a></li></ul></div></div>","javascript":null}